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Background: As a surface glycoprotein, CD147 is capable of stimulating the production of matrix metalloproteinases
(MMPs) from neighboring fibroblasts. The aim of the present study is to explore the role of soluble CD147 on MMPs
secretion from hepatocellular carcinoma (HCC) cells, and to investigate the diagnostic value of serum soluble CD147 in
the HCC detection.
Methods: We identified the form of soluble CD147 in cell culture supernate of HCC cells and serum of patients
with HCC, and explored the role of soluble CD147 on MMPs secretion. Serum CD147 levels were detected by the
enzyme-linked immunosorbent assay, and the value of soluble CD147 as a marker in HCC detection was analyzed.
Results: Full length soluble CD147 was presented in the culture medium of HCC cells and serum of patients with HCC.
The extracellular domain of soluble CD147 promoted the expression of CD147 and MMP-2 from HCC cells. Knockdown
of CD147 markedly diminished the up-regulation of CD147 and MMP-2 which induced by soluble CD147. Soluble
CD147 activated ERK, FAK, and PI3K/Akt pathways, leading to the up-regulation of MMP-2. The level of soluble CD147
in serum of patients with HCC was significantly elevated compared with healthy individuals (P < 0.001). Soluble CD147
levels were found to be associated with HCC tumor size (P = 0.007) and Child-Pugh grade (P = 0.007). Moreover, soluble
CD147 showed a better performance in distinguishing HCC compared with alpha-fetoprotein.
Conclusions: The extracellular domain of soluble CD147 enhances the secretion of MMP-2 from HCC cells, requiring
the cooperation of membrane CD147 and activation of ERK, FAK, and PI3K/Akt signaling. The measurement of soluble
CD147 may offer a useful approach in diagnosis of HCC.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon malignancy and the third leading cause of cancer-
related death worldwide, its incidence is increasing [1].
Interactions among stromal, inflammatory, and cancer
cells create a complex, permissive microenvironment
that favors HCC progression [2]. Matrix metalloprotein-
ases (MMPs) as modulators of tumor microenvironment
play crucial roles in extracellular matrix turnover, cell* Correspondence: znchen@fmmu.edu.cn; hjbian@fmmu.edu.cn
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unless otherwise stated.growth, inflammation, angiogenesis, and tumor cell mi-
gration by both proteolytic and nonproteolytic manners
[3]. CD147, designated as extracellular MMP inducer
(EMMPRIN), is overexpressed in tumor cells and is cap-
able of stimulating the production of various MMPs
such as MMP-1, MMP-2, MMP-3, MMP-9, and MMP-
11 [4,5]. Our previous study demonstrated that CD147
in tumor cells modulates fibroblasts, as well as HCC
cells themselves to produce MMP-2 and MMP-9, pro-
moting HCC invasion and metastasis [6]. Clinical evi-
dences showed that CD147 expression in HCC tissue is
correlated with MMP-2 level and is an independent pre-
dictor of poor survival in patients with HCC [7].
Membrane-bound CD147 may interact with integrin or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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transduction for MMP induction [8-11].
Two forms of soluble CD147 were detected in the con-
ditioned medium of cancer cells, the full-length protein
and the protein containing the extracellular domain. The
full-length CD147 is released by tumor cells via microvesi-
cle shedding, stimulating MMP expression in fibroblasts
through a phospholipase A (2) and 5-lipoxygenase cata-
lyzed pathway [12,13]. CD147 may also shed from cell
membrane via an MMPs-dependent cleavage, generating
soluble CD147 contains either two Ig-like domains or the
N-terminal Ig-like domain [14,15]. It was demonstrated
that recombinant CD147 containing extracellular portion
interacts with membrane-bound CD147 in fibroblasts
[16]. Currently it is well established that soluble CD147
derived from tumor cell acts in a paracrine fashion on
stroma cells to stimulate the production of MMPs, which
consequently contributes to tumor metastasis [17,18]. Al-
though most MMPs in cancer tissue are produced by stro-
mal rather than cancer cells, clinical evidences showed the
tumor cell-expressed MMP-2 and MMP-9 are related with
HCC progress [19,20]. However, little is known the form
and the level of soluble CD147 in patients with HCC and
the regulation of soluble CD147 on MMP expression in
HCC cells. The diagnostic value of serum soluble CD147
for HCC has not been investigated either.
In this study, we identified a full-length soluble CD147
secreted by HCC cells and verified this form in serum of
patients with HCC. We investigated the cooperation be-
tween soluble CD147 and membrane-bound CD147 and
activation of the downstream pathways on secretion of
MMP-2 from HCC cells. Furthermore, we examined
serum soluble CD147 and MMP-2 levels in patients with
HCC and evaluated the results with respect to clinical fea-
tures. We showed that serum soluble CD147 may serve as
a diagnostic marker for HCC, especially for HCC with
negative alpha-fetoprotein (AFP) and HCC at early stage.
Methods
Cell culture
The human HCC cell line SMMC-7721 was obtained from
the Institute of Cell Biology, Chinese Academy of Sciences
(Shanghai, China). 7721-shCD147 cells (CD147 gene is sta-
bly knocked down by shRNA) and T7721 cells (CD147
gene is stably overexpressed) were developed based on
SMMC-7721 cell line and preserved in our laboratory. All
cells were cultured in RPMI 1640 medium (Gibco, NY,
USA) supplemented with 10% fetal bovine serum,
100 μg/ml of penicillin, and 100 μg/ml of streptomycin.
Acetone precipitation of soluble CD147 in conditioned
medium
SMMC-7721 cells were cultured in serum-free medium
for 48 h and the conditioned medium was harvested.Protein sample was placed in an acetone-compatible
tube. Cold (4°C) acetone was added to the tube and mixed
by vortex. The mixture was then incubated for 60 min
on ice. After centrifugation for 10 min at 13,000 × g, the
supernatant was properly disposed. The protein pellet
was resuspended in cold acetone and the precipitation
step was repeated. Samples were analyzed by immunoblot-
ting with antibodies against extracellular CD147 (HAb18
antibody, prepared by our laboratory) [21] or intracellular
CD147 (C-19 antibody, Santa Cruz Biotechnology, CA,
USA).
Preparation of extracellular and intracellular domains of
CD147
The prokaryotically and eukaryotically expressed extracel-
lular CD147 (named as P-CD147ECD and E-CD147ECD,
respectively) were prepared as previously described [22].
The cDNA fragment encoding CD147 intracellular do-
main (residues 227–269) was amplified by PCR, in which
Nde I and Xho I restriction enzyme sites had been added,
respectively. The PCR product was digested with Nde I
and Xho I and ligated into the expression vector pGEX,
which produced CD147 intracellular domain with a GST
tag at the N-terminus. The plasmids were transformed
into Escherichia coli strain BL21 (DE3), and protein ex-
pression was induced with 100 mg/L isopropyl-β-D-1-
thiogalactopyrano-side. After 20 h of growth, GST-CD147
intracellular domain was purified from the soluble frac-
tion using a Glutathione Sepharose 4B- column (GE
Healthcare Life Sciences, New Jersey, USA). The GST tag
was removed with PreScission™ Protease (GE Healthcare
Life Sciences) at 4°C overnight, and CD147 intracellular
domain was purified by gel filtration with Superdex 75
column in 20 mmol/L HEPES buffer (pH 7.3). The pro-
karyotically expressed intracellular CD147 was named as
P-CD147ICD.
Western blot
Proteins were separated by 10% SDS-containing poly-
acrylamide gel electrophoresis and transferred to a poly-
vinylidene fluoride microporous membrane (Millipore,
MA, USA). The membrane was probed with primary anti-
bodies including HAb18, C-19 (Santa Cruz Biotechnology),
anti-MMP-2 (Santa Cruz Biotechnology), anti-p-ERK1/2,
anti-p-FAK, anti-p-Akt, anti-p-EGFR, anti-ERK1/2,
anti-Akt, anti-EGFR (Cell Signaling Technology, Danvers,
USA), anti-FAK (BD), and anti-α-tubulin antibodies (Santa
Cruz Biotechnology).
Immunoprecipitation of serum soluble CD147
Immunoprecipitation was performed to detect the soluble
CD147 in serum samples of patients with HCC using the
Pierce Direct Immunoprecipitation Kit (Pierce Biotechnol-
ogy, Rockford, USA). The agaroseresin were incubated
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Subsequently, the preformed agarose-antibody complexes
were incubated overnight at 4°C with serum samples. The
flow-through fractions of serum samples were also re-
served. After washing to remove unbound components of
the sample, the antigen was recovered by dissociation
from the antibody with elution buffer supplied in the kit.
Samples were analyzed by immunoblotting with C-19 or
HAb18 antibodies.RNA interference
Transfection of small interfering RNAs was performed
using Lipofectamine 2000 (Invitrogen, Carlsbad, USA).
siRNA targeting CD147 (5′-GTACAAGATCACTGACT
CT-3′) and silencer negative control siRNA (snc-RNA)
were synthesized by Shanghai GenePharma Co., Ltd,
China.Immunofluorescence
SMMC-7721, 7721-shCD147, and T7721 cells were
grown on confocal dishes for 24 h, and fixed with 4%
paraformaldehyde. Cells were incubated with HAb18
antibody, followed by fluorescent staining with Alexa
Fluor 488-conjugated anti-mouse IgG (Invitrogen). Cell
nuclei were stained with 4′,6-diamidino-2-phenylindole
(DAPI). Images were obtained with an FV1000 laser
scanning confocal microscope (Olympus, Japan).Real-time PCR
SYBR-Green real-time RT-PCR was performed as previ-
ously described [23] using SYBR Premix EX Taq II (2 ×)
(Takara, Japan) with the sequence detection system
Stratagene Mx3005P (Agilent Technologies, Germany).
The mRNA level of specific genes was normalized against
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). All
primers were listed in Table 1, synthesized by Shanghai
Sangon Biological Engineering Technology & Services
Co., Ltd.Table 1 Sequences of real-time PCR primers
Gene
Forward
CD147 5′-ACTCCTCACCTGCTCCTTGA-3′
MMP-1 5′-GAAGAATGATGGGAGGCAAGT-3
MMP-2 5′-GGCAGTGCAATACCTGAACACC
MMP-3 5′-TTTTACCCTTTTGATGGACCTG-3′
MMP-9 5′-TTCCCCTTCACTTTCCTGGGTA-3′
MMP-13 5′-TCTTCGGCTTAGAGGTGACTG-3′
GAPDH 5′-GCACCGTCAAGGCTGAGAAC-3′Gelatin zymography
SMMC-7721 cells were cultured in the serum-free medium
containing 0, 0.1, 1, 10, or 100 μg/ml E-CD147ECD for
48 h. Conditioned medium was harvested and the activity
of MMP-2 was assayed by gelatin zymography as described
previously [23].Enzyme-linked immunosorbent assay (ELISA)
Serum samples and sections of liver tissues were supplied
by Beijing Youan Hospital, Capital Medical University.
Informed consent has been obtained and the study was
conducted with the approval of the institutional ethics
board of Beijing Youan Hospital of Capital Medical Uni-
versity. The clinical and demographic characteristics of
patients with HCC were shown in Table 2. The concentra-
tions of soluble CD147 and MMP-2 were measured by
ELISA. Soluble CD147 levels were assessed using a spe-
cific Human EMMPRIN/CD147 Quantikine ELISA Kit
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s protocol. Serum MMP-2 levels were mea-
sured with human MMP-2 ELISA kits (Senxiong Biotech,
Shanghai, China). The concentration in each sample well
was determined by interpolation from a standard curve.
Each sample was tested in duplicate.Immunohistochemistry
Formaldehyde-fixed and paraffin-embedded sections of
liver tissue were subjected to immunohistochemistry
and stained with monoclonal antibodies against CD147
or MMP-2 using the streptavidin-peroxidase staining kit
(ZSGB-Bio., Beijing, China). The percentage of the posi-
tive cells were graded on a scale of 0 to 4 (0: negative, 1:
0–25%, 2: 26–50%, 3: 51–75%, 4: 76–100%). Areas that
showed positivity were further quantified from 0 to 3 by
the relative staining intensity (1: weak, 2: moderate, 3:
intensive). The final score was obtained by multiplying
the intensity and quantification measurements. Images
were obtained with an inverted microscope (CKX41;
Olympus) equipped with a digital camera under 400×
magnification.Primer sequences
Reverse
5′-GCCTCCATGTTCAGGTTCTC-3′
′ 5′-GAGGACAAACTGAGCCACATC-3′
-3′ 5′-GTCTGGGGCAGTCCAAAGAACT-3′
5′-GTCCCTGTTGTATCCTTTGTCC-3′
5′-CGCCACGAGGAACAAACTGTAT-3′
5′-CAGAGGAGTTACATCGGACCA-3′
5′-TGGTGAAGACGCCAGTGGA-3′
Table 2 Clinical and demographic characteristics of
patients with HCC
Characteristics n = 62
Age, years
Mean ± SD 56.6 ± 8.6
Median 57.5
Range 40–77
Sex, n (%)
Male 53 (85.5)
Female 9 (14.5)
Hepatitis history, n (%)
Yes 58 (93.5)
Hepatic cirrhosis, n (%)
Yes 56 (90.3)
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Mann–Whitney test or Kruskal-Wallis test was used to
compare levels of serum CD147 or MMP-2 in different
groups with variable clinicopathologic features. Logistic
regression was used to evaluate the association between
soluble CD147 and HCC risk. A Spearman’s correlation
test was used to assess the correlation of serum CD147
levels with CD147 or MMP-2 levels in HCC tissues. Re-
ceiver operating characteristic (ROC) curve analysis was
done to calculate area under the curve (AUC) and to
identify cutoff points. AUC values and 95% confidence
intervals (CI) were used to summarize diagnostic per-
formance of CD147 and AFP. Unless otherwise stated,
the results were expressed as mean ± standard deviation.
One-way ANOVA test and t-test were performed for
other experiments to compare the mean values. The P
values and data were obtained from three independent
experiments. Statistical significance was set at P < 0.05.
Adobe Photoshop CS6 was used to quantify the intensity
of bands on western blot. The GraphPad Prism software
and SPSS 17.0 software were used for statistical analysis.
Results
Full-length soluble CD147 was presented in conditioned
medium of HCC cells
The soluble form of CD147 has been detected in condi-
tioned medium of tumor cells as either a full-length pro-
tein, a protein lacking the transmembrane and cytoplasmic
domains, or a segment only containing the N-terminal
Ig-like domain [13,15]. Here we tried to identify the
form of soluble CD147 from HCC cells. The serum-free
conditioned medium and SMMC-7721 cell lysates were
subjected to western blotting for two types of CD147
antibodies. One is HAb18 antibody reacting against
extracellular domain of CD147, and the other is commer-
cial C-19 antibody reacting against intracellular domain of
CD147. The immunoblot analysis using HAb18 antibodyconfirmed the presence of soluble CD147 in the condi-
tioned medium of HCC cells, yielding a band with molecu-
lar weight between 45–66 kDa (Figure 1A). While C-19
antibody also detected CD147 in the conditioned medium
(Figure 1B), demonstrating the presence of intracellular
domain of soluble CD147. Meanwhile, the eukaryotically
expressed extracellular domain of CD147 (E-CD147ECD)
[22] showed a 35 kDa-band by HAb18 antibody, and were
undetected by C-19 antibody (Figure 1A and B). We con-
cluded that a full-length soluble CD147 was present in the
conditioned medium of HCC cells.
MMP-2 upregulation mediated by extracellular domain of
soluble CD147 core protein
To evaluate the effect of soluble CD147 on expression of
MMPs in HCC cells, we tested the various types of MMPs,
including MMP-1, −2, −3, −9, and MMP-13 in SMMC-
7721 cells. Real-time PCR revealed a significant upregula-
tion of MMP-2 under the stimulation of E-CD147ECD for
6 h (Figure 1C). We then evaluated MMP-2 mRNA level in
response to different doses of E-CD147ECD in SMMC-
7721 cells. The E-CD147ECD increased MMP-2 expres-
sion in a concentration-dependent manner, and 10 μg/ml
CD147 had the greatest effect on stimulation of MMP-2
mRNA expression (P < 0.01) (Figure 1D). The secretion
of MMP-2 in supernatant was also increased with re-
combinant CD147 stimulation as demonstrated by SDS-
polyacrylamide gelatin zymography (Figure 1E). Next,
HCC cells were treated with E-CD147ECD and prokar-
yotically expressed extracellular domain of CD147 (P-
CD147ECD) for 6 h, respectively. We found that both
prokaryotically and eukaryotically expressed extracellular
CD147 promoted the MMP-2 expression with a similar
efficiency, indicating the core protein but not the glyco-
sylation plays the functional role (Figure 1F). In order to
validate the role of extracellular domain of soluble
CD147 in mediating the upregulation of MMP-2 expres-
sion, P-CD147ECD and prokaryotically expressed intra-
cellular CD147 (P-CD147ICD) were used. As shown in
Figure 1G, intracellular CD147 did not significantly up-
regulated MMP-2 expression, further demonstrating the
regulation of MMP-2 was mediated by the extracellular
domain of soluble CD147.
Efficient induction of MMP-2 by extracellular
domain of soluble CD147 required cooperation
with membrane-bound CD147
To detect whether the membrane-bound CD147 was
correlated with induction of MMP-2 upon the stimulant
soluble CD147ECD, we generated two cell lines by
stable transfection of the CD147 small hairpin RNA
(shCD147) and human CD147 cDNA into SMMC-7721
cells, named 7721-shCD147 and T7721, respectively.
Immunofluorescence assay demonstrated that shCD147
Figure 1 MMPs expression in HCC cells under the stimulation of soluble CD147. Eukaryotically expressed extracellular CD147 (E-CD147ECD),
serum-free conditioned medium, and SMMC-7721 cell lysates were subjected to western blotting. HAb18 reacting against extracellular CD147 (A)
and C-19 reacting against intracellular CD147 (B) were used respectively. (C) Real-time PCR was performed to test mRNA levels of MMP-1, −2, −3, −9,
and MMP-13 in SMMC-7721 cells in the absence or presence of 10 μg/ml E-CD147ECD for 6 h. (D) Soluble CD147 increased the expression of MMP-2
in a concentration-dependent manner. SMMC-7721 cells were treated with different concentrations of E-CD147ECD for 6 h and MMP-2 mRNA
level was analyzed using real-time PCR. (E) SMMC-7721 cells were treated with different concentrations of E-CD147ECD and MMPs levels were
analyzed using gelatin zymography. (F) SMMC-7721 cells were treated with prokaryotically expressed extracellular CD147 (P-CD147ECD) or
E-CD147ECD for 6 h and MMP-2 mRNA level was analyzed using real-time PCR. GAPDH was used as a normalization control. *P < 0.05. (G)
Real-time PCR showed mRNA level of MMP-2 in SMMC-7721 cells treated with P-CD147ECD or prokaryotically expressed intracellular CD147
(P-CD147ICD) for 6 h. GAPDH was used as a normalization control in all real-time PCR analysis. *P < 0.05, **P < 0.01.
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CD147 levels, while location of CD147 on cell mem-
brane was increased with CD147 cDNA transfection
(Figure 2A). Western blotting analysis of cell lysates
showed that a distinct loss of MMP-2 expression in
7721-shCD147 cells and a significant increase of MMP-2
level in T7721cells (Figure 2B), which was consistent with
the results of real-time PCR (Figure 2C). These results sug-
gest that membrane-bound CD147 is involved in the
MMP-2 production. When the three cell lines were treated
with 10 μg/ml of E-CD147ECD, real-time PCR indicated
that CD147 was autocrine-upregulated with 1.20-, 1.42-,
and 1.82-folds in 7721-shCD147, SMMC-7721, and T7721cells, and MMP-2 expression was enhanced with 1.20-,
1.63-, and 1.78-folds (Figure 2D). The elevated tendency of
both MMP-2 and CD147 expression was appropriated with
the membrane-bound CD147 levels in the three cell
lines after soluble CD147 stimulation. The CD147-
targeted siRNA (si-CD147) led to a marked reduction of
CD147 mRNA level in SMMC-7721 cells during 24 h, as
compared with snc-RNA (P < 0.001). When the cells were
stimulated with E-CD147ECD, siCD147 significantly inhib-
ited the upregulation of MMP-2 mRNA level, and CD147
expression as well (P < 0.001) (Figure 2E). These results in-
dicate that membrane CD147 plays an important role in
the regulation of soluble CD147 on MMP-2 expression.
Figure 2 (See legend on next page.)
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Figure 2 Cooperation of soluble CD147 and membrane-bound CD147 in the induction of MMP-2 in HCC cells. (A) Immunofluorescence
of membrane-bound CD147 in SMMC-7721 cells, 7721-shCD147 cells, and T7721 cells detected by confocal laser scanning microscopy (×600).
(B) The protein levels of CD147 and MMP-2 were analyzed by western blotting. Blots were probed for α-tubulin to ensure equal protein loading.
Western blot scanning densitometry for three independent experiments. (C) The mRNA levels of CD147 and MMP-2 were analyzed by real-time
PCR. (D) SMMC-7721 cells, 7721-shCD147 cells, and T7721 cells were treated with E-CD147ECD for 6 h and analyzed for CD147 and MMP-2 mRNA
expression using real-time PCR. (E) Real-time RT-PCR detection of CD147 and MMP-2 mRNA levels in SMMC-7721 cells transfected with si-CD147
followed by stimulation with 10 μg/ml E-CD147ECD at different time points. Cells were transfected with snc-RNA as a control. GAPDH was used
as a normalization control. *P < 0.05, **P < 0.01, ***P < 0.001.
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regulation of MMP-2 expression by soluble CD147
To define the possible regulatory role of CD147 down-
stream pathways on MMP-2 level, the SMMC-7721 cells
were cultured with E-CD147ECD at the concentration
10 μg/ml for 30 min followed by detection of molecular
phosphorylation. As shown in Figure 3A, E-CD147ECD in-
creased the phospho-ERK1/2, phospho-FAK, and phospho-
Akt contents but not phospho-EGFR content. The pro-
tein levels of CD147 and MMP-2 were elevated at 12 h
post treatment (Figure 3B). In order to confirm the involve-
ment of ERK, FAK, and PI3K/Akt signalings in upregulat-
ing MMP-2, cells were pre-treated with inhibitors U0126,
FAK inhibitor 14, LY294002 (Cell Signaling Technology,Figure 3 Involvement of ERK, FAK, and PI3K/Akt pathways in upregul
cultured for 30 min (A) and 12 h (B) with 10 μg/ml of E-CD147ECD. CD147 an
determinations of CD147 or MMP-2/α-tubulin ratio. (C) SMMC-7721 cells w
pre-treatment with ERK inhibitor (U0126), FAK inhibitor (FAK inhibitor 14),
expression levels of phospho-ERK1/2, ERK1/2, phospho-FAK, FAK, phospho
blotting. Quantitative analysis of phosphorylated fraction relative to the total f
to 1. *P < 0.05, **P < 0.01, ***P < 0.001.Danvers, USA), or the three combination followed by incu-
bation with E-CD147ECD for 12 h. As seen in Figure 3C,
the increase in protein abundance for MMP-2 elicited by
soluble CD147 was inhibited in the presence of each in-
hibitor, whereas the presence of all three inhibitors
completely suppressed the MMP-2 increase. Taken to-
gether, these findings demonstrate that ERK, FAK, and
PI3K/Akt pathways are all involved in soluble CD147-
induced upregulation of MMP-2.
Full-length soluble CD147 and secreted MMP-2 levels
were elevated in patients with HCC
To evaluate the release of soluble CD147 in blood, we tested
the serum of four HCC patients. Immunoprecipitation wasation of MMP-2 driven by soluble CD147. SMMC-7721 cells were
d MMP-2 data were expressed as means ± SEM of three independent
ere treated with E-CD147ECD (10 μg/ml) for 12 h with or without
PI3K inhibitor (LY294002), or combined inhibitors. In A and C, the
-Akt, Akt, phospho-EGFR, and EGFR were detected by western
raction was shown. Mean values for control groups were normalized
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with C-19 antibody. All the four HCC patients were de-
tected the full-length soluble CD147 in serum by variation
levels (Figure 4A). Furthermore, immunoprecipitation was
performed with C-19 antibody, and the samples containing
bait:prey complexes and the flow-through fractions were de-
tected with HAb18 antibody by western blotting, respect-
ively. As shown in Figure 4B, the full-length soluble CD147
was detected in the bait:prey complex from number 4 pa-
tient. However, a very weak level of soluble CD147 was de-
tected in the bait:prey complex from healthy individual. The
flow-through fractions were concentrated up to four-fold
and then analyzed by western blot. A much lower level of
full-length soluble CD147 was observed in the concentrated
flow-through fraction from number 4 patient, and no extra-
cellular domain of CD147 was detected. These results im-
plied that full-length CD147 constituted the majority of
soluble CD147 in serum of HCC patients. Serum soluble
CD147 and secreted MMP-2 were then examined by ELISA
in 62 patients with HCC and 25 healthy individuals. As
shown in Figure 4C, serum soluble CD147 and secreted
MMP-2 levels were significantly higher in HCC patients
than in healthy individuals (P < 0.001) (CD147: HCC, me-
dian 4.483 ng/ml, range 2.218–20.820 ng/ml; healthy, me-
dian 2.811 ng/ml, range 1.956–5.260 ng/ml. MMP-2: HCC,
median 105.7 ng/ml, range 18.2–797.5; healthy, median
28.6 ng/ml, range 5.5–224.2 ng/ml). However, serum soluble
CD147 showed no significant correlation with secreted
MMP-2 levels in patients with HCC (Additional file 1:
Figure S1). Logistic regression model was further used
to analyze the association of soluble CD147 level with
HCC risk by estimating odds ratio (OR). Receiver oper-
ating characteristic (ROC) curve analysis was done to
evaluate the optimal cutoff point, which was given by
the maximum of the Youden index. In logistic regres-
sion analysis, soluble CD147 greater than the cutoff
(3.3 ng/ml) had increased HCC risk (OR = 16.467, 95%
CI: 5.264–51.507, P < 0.001).
Positive correlation of soluble CD147 with
membrane-bound CD147 and MMP-2 in patients with HCC
We collected 26 pairs of serum and HCC biopsy tissues.
Immunohistochemistry of HCC tissues revealed the loca-
tion of CD147 on cell membrane within tumor compart-
ment and MMP-2 expression in both tumoral and stromal
compartments (Figure 4D). In total, 16 of 26 HCC cases
(61.5%) showed overexpression of CD147 and 12 of 15
HCC cases (80.0%) indicated MMP-2 overexpression. The
score of membrane-bound CD147 expression in tumors
was positively correlated with the concentration of soluble
CD147 in serum (r = 0.594, P = 0.001) (Figure 4E). MMP-2
level in tumor loci was scored and showed a positive cor-
relation with the concentration of soluble CD147 in serum
(r = 0.650, P = 0.009) (Figure 4E).Positive correlation of soluble CD147 with serum AFP
level in patients with HCC
The correlation of soluble CD147 level and secreted
MMP-2 with AFP level was evaluated, respectively. As
shown in Figure 4F, soluble CD147 level was significantly
higher in serum of patients with AFP level over 20 ng/ml
than in patients with lower AFP level (P < 0.01). However,
no statistical significance was observed between MMP-2
levels in serum of patients with different AFP levels.
Correlation of serum soluble CD147 with
clinicopathologic features of HCC patients
The levels of soluble CD147 correlated with variable
clinicopathologic factors were summarized in Table 3.
The CD147 concentration was elevated in patients with
Child-Pugh grade B compared with that with Child-
Pugh grade A (P = 0.007). Elevation of CD147 concentra-
tions was found with increased tumor size (P = 0.007). It
was also significantly higher in patients with advanced
HCC (BCLC stage C) as compared with very early HCC
(BCLC stage 0) (P = 0.044). As shown in Table 4, serum
MMP-2 levels showed no significant correlation with
clinicopathologic features of HCC patients.
Better diagnostic performance of serum CD147 compared
with AFP in HCC
We analyzed the ROC curves to evaluate the efficacy of
serum CD147 as a diagnostic biomarker for distinguish-
ing HCC patients from healthy individuals (Figure 5A).
AUC for serum CD147 was 0.857, indicating excellent
discrimination (95% CI: 0.775–0.940). Although AUC
for serum CD147 was found to be larger than that of
serum AFP (0.813; 95% CI: 0.726–0.900, Additional file
2: Figure S2), no statistical significance was observed.
Optimal cutoff point of serum CD147 was 3.3 ng/ml,
which provided a sensitivity of 83.9% (52 of 62 HCC pa-
tients correctly classified) and a specificity of 76.0% (19
of 25 controls correctly classified). The currently recom-
mended clinical cutoff value (20 ng/ml) was used for
AFP, and the sensitivity of AFP (48.4%) was much lower
than that of serum CD147. We also noticed an accept-
able discrimination of serum CD147 for distinguishing
AFP-negative (<20 ng/ml) HCC patients from healthy
individuals (AUC, 0.793; 95% CI: 0.677–0.909) (Figure 5B).
Based on the optimal cutoff value of 3.3 ng/ml, 25 of 33
AFP-negative HCC patients were correctly classified
(75.8%). We next focused on the subset of patients with
early stage HCC (BCLC 0–A). Serum CD147 had an ex-
cellent performance for distinguishing early stage HCC
(BCLC A) as well as very early stage HCC (BCLC 0) from
healthy controls (Figure 5C, D). In detecting HCC of
BCLC 0–A stage, the sensitivity of serum CD147 was
much higher than that of AFP (87.1% vs. 45.2%, Table 5).
Even in HCC with BCLC 0 stage, serum CD147 showed
Figure 4 (See legend on next page.)
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Figure 4 Soluble CD147 and MMP-2 levels in the serum of HCC patients and healthy individuals. (A) Serum samples of four HCC patients
were immunoprecipitated for CD147 extracellular domain by HAb18 and immunoblotted for CD147 intracellular domain by C-19 antibody. (B)
Serum samples of a healthy individual and number 4 patient with HCC were immunoprecipitated for CD147 intracellular domain by C-19
antibody, and the samples containing bait:prey complexes and the flow-through fractions were detected with HAb18 antibody, respectively. (C)
Serum levels of soluble CD147 and MMP-2 were determined by ELISA assay. Bars indicated mean values in each group. (D) Expression of CD147
and MMP-2 in human HCC tissues assessed by immunohistochemistry (×400). Representative positive and negative samples were shown. (E)
Correlation of serum soluble CD147 level with membrane-bound CD147 (n = 26) and MMP-2 expression (n = 15) in HCC tissues. (F) Comparison of
serum soluble CD147 and serum MMP-2 in HCC patients with different AFP levels. Serum AFP levels were examined by electrochemiluminescence
analyzer in Xijing Hospital of Fourth Military Medical University. Bars indicated mean values in each group.
Wu et al. Journal of Translational Medicine 2014, 12:190 Page 10 of 13
http://www.translational-medicine.com/content/12/1/190higher sensitivity than that of AFP (83.3% vs. 41.7%).
These results suggest that serum soluble CD147 is a more
sensitive marker superior to serum AFP in detecting
HCC, including HCC at early stage.
Discussion
CD147 is found to be overexpressed in many cancers,
suggesting that it serves as a key regulator for oncogen-
esis and cancer metastasis [23,24]. In addition to the ex-
pression as a membrane-bound form, a soluble form of
CD147 has been detected in cultured supernatants of
cancer cells and human body fluids [13,17,18,25-29]. Al-
though both the full-length soluble CD147 and the extra-
cellular domain of CD147 in the conditioned medium of
several types of cancer cells had been detected, which kind
of forms existed in the serum of cancer patients was still
unkown. In this study, we found the secretion of intact
CD147 from HCC cells and verified this presence in the
serum of patients with HCC. Over-expression of CD147Table 3 Relationship between soluble CD147 and variable
clinicopathologic features
Clinicopathologic
features
n = 50 Soluble CD147 P
valueRange (ng/ml) Median (ng/ml)
Child-Pugh grade 0.007
A 37 2.218–19.890 4.308
B 13 3.306–20.820 5.727
Tumor number 0.470
Single 28 2.727–19.890 4.427
Multiple 22 2.218–20.820 5.232
Tumor size (cm) 0.007
<3 24 2.818–6.382 4.301
3–5 17 2.218–20.820 4.308
≥5 9 4.484–12.370 5.845
BCLC stage 0.195
0 12 2.973–6.220 3.991
A 19 2.727–19.890 4.482
B 13 2.218–20.820 4.909
C# 6 3.745–12.370 6.359
#Significant difference as compared with BCLC 0 group (P = 0.044). BCLC
denotes Barcelona Clinic Liver Cancer Staging System.gene into human breast cancer cells elevated soluble
CD147 level, indicating the soluble CD147 release is cor-
related with the degree of CD147 expression in tumor
cells [17]. In our study, the concentration of soluble
CD147 in serum was positively correlated with CD147 ex-
pression level in HCC tissues, which was consistent with
the findings in vitro and suggests that CD147 was secreted
from tumor cells, possibly by vesicle shedding.
The homophilic interaction between soluble CD147 and
its cognate receptor in cells has been demonstrated to
stimulate the expression of MMPs in fibroblasts and tumor
cells [16]. We showed that only the extracellular domain of
soluble CD147 core protein was indispensable for the
MMP-2 inducing activity, demonstrating the essential role
of this domain in homophilic interactions. By gain- and
loss-of-function strategies, the induction of MMP-2 by sol-
uble CD147 was showed dependent with expression of cell
associated-CD147. We also observed that soluble CD147
stimulated the upregulation of cell associated-CD147, dis-
playing an autocrine CD147 feedback loop in HCC cells.Table 4 Relationship between serum MMP-2 and variable
clinicopathologic features
Clinicopathologic
features
n = 50 Serum MMP-2 P
valueRange (ng/ml) Median (ng/ml)
Child-Pugh grade 0.401
A 37 18.2–679.1 108.1
B 13 28.7–316.1 98.7
Tumor number 0.899
Single 28 18.2–679.1 104.3
Multiple 22 20.4–590.6 99.3
Tumor size (cm) 0.284
<3 24 18.2–679.1 115.5
3–5 17 20.4–419.3 70.2
≥5 9 28.7–172.7 62.5
BCLC stage 0.270
0 12 18.2–679.1 113.1
A 19 40.3–590.6 113.0
B 13 20.4–168.1 61.4
C 6 40.4–411.0 101.9
Figure 5 ROC curves used to predict performance of soluble CD147 for distinguishing HCC from healthy controls. (A) ROC curve
evaluating those with HCC (n = 62) and healthy controls (n = 25). (B) ROC curve evaluating those with AFP-negative HCC (n = 33) and healthy con-
trols (n = 25). (C) ROC curve evaluating those with early stage HCC (n = 31) and healthy controls (n = 25). (D) ROC curve evaluating those with very
early stage HCC (n = 12) and healthy controls (n = 25).
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mal human fibroblasts of lung by other group [17].
Purified recombinant CD147 protein activates multiple
transcription factors in cardiomyocytes and induces
interleukin-18 expression via Rac1-dependent PI3K/Akt/
IKK/NF-κB and MKK7/JNK/AP-1 signaling [30]. Our
previous studies had proven the production of MMPs
from HCC cells induced by recombinant CD147, and
the activation of ERK signaling might be involved [31].
Here, by incubating HCC cells with recombinant extra-
cellular CD147, we observed increased phosphorylation
of ERK1/2, FAK, and Akt, but not that of EGFR. A com-
bined treatment of inhibitors targeting these pathways
completely inhibited expression of MMP-2, demonstratingTable 5 Sensitivity of serum CD147 and AFP in HCC
patients according to BCLC stage
Serological
marker
Cut off
value (ng/ml)
BCLC stage
0 n (%) 0–A n (%)
Serum CD147 3.3 10 (83.3) 27 (87.1)
AFP 20 5 (41.7) 14 (45.2)
Combined 3.3; 20 11 (91.7) 29 (93.5)the cooperation of ERK, FAK, and PI3K/Akt pathways in
soluble CD147-regulated MMP-2 expression. Previous
study in our lab had showed a crucial role of membrane-
bound CD147-integrin interaction in activation of FAK-
PI3K pathway for MMPs expression [8,10]. It is reasonable
to presume FAK signaling and PI3K/Akt signaling as po-
tential pathways involved in soluble CD147-induced
MMP-2 expression through membrane-bound CD147. It
is worth to note other receptors may exist for soluble
CD147 in ERK1/2 signaling transduction [16].
To determine relative mass values for naturally occur-
ring soluble CD147, we used the Quantikine Human
EMMPRIN kit produced by R&D Systems, Inc. In contrast
to a previous study [26], we found significantly higher
soluble CD147 levels in HCC patients than in healthy
individuals. This results leads to the suggestion that the
measurement of serum soluble CD147 may offer a use-
ful approach in the early diagnosis and risk stratification
of HCC. Although MMP-2 levels in patients with HCC
were also found to be significantly higher than that in
controls, there was no significant correlation between
serum MMP-2 and serum soluble CD147. A previous
study showed that serum MMP-2 levels in HCC patients
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ease without this malignancy, indicating MMP-2 may not
be used as a serologic marker for HCC [32].
AFP is the most utilized diagnostic serum marker for
HCC [33]. However, nonspecific elevation was found in
patients with liver cirrhosis and chronic hepatitis. In
addition, normal AFP levels are present in many patients
with early stage HCC, thus the accuracy of serum AFP
in early diagnosis of HCC was not satisfying [34]. In our
study, serum soluble CD147 showed significant advan-
tages to distinguish HCC compared with AFP, including
early HCC and HCC with normal serum AFP levels. The
combination of soluble CD147 and AFP further improved
the detective sensitivity of early stage HCC, implying a
promising strategy for early diagnosis of HCC.
Conclusions
Although membrane CD147 has been proven to be an
independent predictor of poor survival in HCC patients,
little is known of the diagnostic value of soluble CD147
in HCC detection. Here we found extracellular domain
of soluble CD147 enhances the secretion of MMP-2 from
HCC cells, requiring the cooperation of membrane
CD147 and activation of ERK, FAK, and PI3K/Akt signal-
ing. Serum soluble CD147 was elevated in HCC patients
compared with healthy individuals and was associated
with tumor size and Child-Pugh grade. Moreover, serum
soluble CD147 showed a better performance in distin-
guishing HCC compared with AFP. Our study supports
the use of soluble CD147 as a diagnostic marker in HCC
detection, especially for HCC with negative AFP and HCC
at early stage. Identification of this potential serologic
marker may help to present the best chance for curative
treatment and to improve outcomes. The study also pro-
vides a new insight into the role of soluble CD147 in
MMP-2 secretion and HCC progression.
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